Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus HEATHER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus HEATHER.
CU-7 vs HEATHER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Heather is a combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone, a spironolactone analog with anti-mineralocorticoid activity, also inhibits ovulation and may increase cervical mucus viscosity, impeding sperm penetration.
50 mg orally once daily
5 mg orally once daily, increased to 10 mg after 2 weeks if tolerated; maximum 20 mg daily.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life: 4-6 hours. Clinical context: Requires every-6-hour dosing for steady state; therapeutic drug monitoring recommended in renal impairment.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Renal excretion of unchanged drug (60%) and hepatic metabolism with biliary/fecal elimination (40%).
Category C
Category C
Contraceptive
Contraceptive